Treatment of Severe Yellow Fever with Liver Failure (Hepatic Organ Dysfunction)

This protocol addresses a high-risk presentation: severe yellow fever in the setting of liver failure (hepatic organ dysfunction). Hepatic involvement at this level alters both monitoring strategy and treatment approach in ways that differ from uncomplicated yellow fever.

Liver failure is a recognised severe complication of yellow fever. Its presence has direct implications for clinical monitoring in this population.

In research settings only, an investigational monoclonal immunoglobulin is among the antiviral approaches being evaluated for patients with suspected or confirmed yellow fever. Access to this type of therapy is restricted to formal clinical trial frameworks — it is not registered for this indication outside research use.

The complete regimen, full scope of options, and clinical decision pathway are detailed in the structured protocol below.

The primary clinical target in this population is viral clearance — confirmed absence of yellow fever viraemia.